Henry J L, Coggin D L, King C R
Oncogene Research, Molecular Oncology, Inc., Gaithersburg, Maryland 20878.
Cancer Res. 1993 Mar 15;53(6):1403-8.
The erbB-2 (or HER-2 or neu) gene is amplified and overexpressed in approximately one-third of cancers of the breast, stomach, and ovary. Evidence is accumulating that erbB-2 overexpression is associated with decreased survival of breast cancer patients. In an effort to understand how erbB-2 overexpression might impart a more malignant potential to breast cancer cells, we have searched for evidence of changes in gene expression associated with erbB-2 overexpression. Using differential screening of a complementary DNA library we identified several complementary DNAs that represent mRNAs the expression of which may vary according to erbB-2 level. One complementary DNA was studied in detail. The mRNA encoding the ribosomal protein L19 (1.9 kilobases) was more abundant in breast cancer samples that express high levels of erbB-2 (P < 6 x 10(-7)). The level of L19 mRNA expression varied over a 1- to 64-fold range among the tumor samples. No evidence of gene amplification for L19 was identified. The L19 overexpression in these breast tumor samples was not associated with the increased expression of the mRNAs for other ribosomal proteins (S16 and L26).
erbB - 2(或HER - 2或neu)基因在大约三分之一的乳腺癌、胃癌和卵巢癌中发生扩增并过度表达。越来越多的证据表明,erbB - 2过度表达与乳腺癌患者生存率降低有关。为了了解erbB - 2过度表达如何赋予乳腺癌细胞更高的恶性潜能,我们寻找了与erbB - 2过度表达相关的基因表达变化的证据。通过对互补DNA文库进行差异筛选,我们鉴定出了几个互补DNA,它们代表的mRNA表达可能会根据erbB - 2水平而变化。我们对其中一个互补DNA进行了详细研究。编码核糖体蛋白L19(1.9千碱基)的mRNA在高表达erbB - 2的乳腺癌样本中更为丰富(P < 6×10⁻⁷)。在肿瘤样本中,L19 mRNA表达水平在1至64倍的范围内变化。未发现L19基因扩增的证据。这些乳腺肿瘤样本中L19的过度表达与其他核糖体蛋白(S16和L26)的mRNA表达增加无关。